Hyponatremia Correction Rate
The maximum correction rate for hyponatremia should not exceed 8 mmol/L in 24 hours to prevent osmotic demyelination syndrome, with an initial target of 6 mmol/L over 6 hours for severe symptomatic cases. 1
Correction Rate Guidelines Based on Symptom Severity
Severe Symptomatic Hyponatremia (Seizures, Coma, Altered Mental Status)
- Administer 3% hypertonic saline immediately with a target correction of 6 mmol/L over the first 6 hours or until severe symptoms resolve 1, 2
- After achieving the initial 6 mmol/L correction, limit additional correction to only 2 mmol/L in the remaining 18 hours 1, 2
- Total correction must not exceed 8 mmol/L in 24 hours 1, 2, 3
- Administer 100 mL of 3% saline over 10 minutes, repeatable every 10 minutes up to three times if seizures persist 4
- Monitor serum sodium every 2 hours during active correction 1, 4
Asymptomatic or Mildly Symptomatic Hyponatremia
- Target correction of 4-8 mmol/L per day, not exceeding 8 mmol/L in 24 hours 1
- Monitor serum sodium every 4 hours initially, then daily 1
- Implement fluid restriction to 1 L/day for SIADH 1, 4
High-Risk Populations Requiring Slower Correction
Patients with advanced liver disease, alcoholism, malnutrition, severe hyponatremia (<115 mEq/L), or prior encephalopathy require even more cautious correction at 4-6 mmol/L per day 1, 5
- These patients are at substantially higher risk for osmotic demyelination syndrome even with standard correction rates 1, 5
- For serum sodium <115 mEq/L specifically, limit correction to <8 mEq/L in 24 hours 5
- Thiamine supplementation is advisable for any patient with poor dietary intake 5
Critical Safety Thresholds
FDA-Approved Tolvaptan Guidelines
- Too rapid correction (>12 mEq/L/24 hours) can cause osmotic demyelination resulting in dysarthria, mutism, dysphagia, lethargy, affective changes, spastic quadriparesis, seizures, coma and death 3
- In susceptible patients (severe malnutrition, alcoholism, advanced liver disease), slower rates of correction are mandatory 3
- Tolvaptan must be initiated and re-initiated only in a hospital where serum sodium can be monitored closely 3
Recent Evidence on Correction Rates
- While recent meta-analysis data suggest rapid correction (≥8-10 mEq/L per 24 hours) may be associated with lower mortality compared to very slow correction (<4-6 mEq/L per 24 hours), the established guideline limit of 8 mmol/L per 24 hours remains the standard to prevent osmotic demyelination syndrome 1, 6
- Osmotic demyelination syndrome can occur even with correction rates ≤10 mEq/L in 24 hours in high-risk patients with severe hyponatremia 5
Discontinuation Criteria for 3% Saline
Discontinue 3% hypertonic saline when severe symptoms resolve 2
- Transition to mild symptom protocol with fluid restriction to 1 L/day 2
- Switch monitoring from every 2 hours to every 4 hours 2
- Continue treatment until sodium reaches 131 mmol/L 2
- If 6 mmol/L was corrected in the first 6 hours, allow only 2 mmol/L additional correction in the next 18 hours 2
Management of Overcorrection
If sodium correction exceeds 8 mmol/L in 24 hours, immediately discontinue current fluids and switch to D5W (5% dextrose in water) 1
- Consider administering desmopressin to slow or reverse the rapid rise in serum sodium 1, 7
- Therapeutic relowering of serum sodium is supported by animal data and small clinical trials 7
- Target reduction to bring total 24-hour correction to no more than 8 mEq/L from the starting point 1
Common Pitfalls to Avoid
- Overly rapid correction exceeding 8 mmol/L in 24 hours is the most common and dangerous pitfall 1
- Inadequate monitoring during active correction can lead to unrecognized overcorrection 1
- Failing to recognize high-risk patients (liver disease, alcoholism, malnutrition, sodium <115 mEq/L) who require slower correction 1, 5
- Using the same correction rate for acute (<48 hours) versus chronic (>48 hours) hyponatremia—chronic cases require slower correction 1, 8
- Ignoring mild hyponatremia (130-135 mmol/L) as clinically insignificant, when it increases fall risk and mortality 1, 9